D. Alarcon-segovia

发表

Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus

D. Alarcón-Segovia, J. Alcocer-Varela, Y. Lévy, 1995, The Journal of experimental medicine.

The penetration of autoantibodies into cells may induce tolerance to self by apoptosis of autoreactive lymphocytes and cause autoimmune disease by dysregulation and/or cell damage.

D. Alarcón-Segovia, L. Llorente, A. Ruiz-Argüelles, 1996, Journal of autoimmunity.

Antiphospholipid Antibodies and the Antiphospholipid Syndrome in Systemic Lupus Erythematosus A Prospective Analysis of 500 Consecutive Patients

J. Sánchez-Guerrero, D. Alarcón-Segovia, J. Cabiedes, 1989, Medicine.

Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome.

Bihui Huang, J. Sánchez-Guerrero, D. Alarcón-Segovia, 2005, Blood.

The antiphospholipid story.

D. Alarcón-Segovia, D. Alarcon-segovia, 2003, The Journal of rheumatology.

Prophylaxis of the antiphospholipid syndrome: a consensus report

Y. Shoenfeld, D. Alarcón-Segovia, M. Khamashta, 2003, Lupus.

A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans

R. Jonsson, A. Bolstad, A. Brookes, 2002, Nature Genetics.

Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus.

D. Alarcón-Segovia, J. Alcocer-Varela, M. Cardiel, 2000, Arthritis and rheumatism.

The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays.

D. Alarcón-Segovia, M. Amigo, A. Cabral, 1996, The American journal of medicine.

Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus.

D. Alarcón-Segovia, A. Villa, C. Drenkard, 1992, Seminars in arthritis and rheumatism.

Vasculitis in systemic lupus erythematosus

D. Alarcón-Segovia, E. Reyes, C. Drenkard, 1997, Lupus.

Fatal pulmonary hemorrhage in systemic lupus erythematosus. Occurrence without hemoptysis.

D. Alarcón-Segovia, E. Díaz-Jouanen, C. Abud-Mendoza, 1985, The Journal of rheumatology.

Exposure of anionic phospholipids upon platelet activation permits binding of beta 2 glycoprotein I and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects.

D. Alarcón-Segovia, Y. Richaud-Patin, J. Vázquez-Mellado, 1994, Journal of autoimmunity.

Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies.

J. Sánchez-Guerrero, D. Alarcón-Segovia, C. Lavalle, 1990, The Journal of rheumatology.

The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients With Systemic Lupus Erythematosus: Ethnic and Disease Heterogeneity Among “Hispanics”

E. Soriano, D. Alarcón-Segovia, B. Pons-Estel, 2004, Medicine.

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study.

R. Bagin, V. Strand, D. Alarcón-Segovia, 2003, Arthritis and rheumatism.

Diversity and pattern of inheritance of autoantibodies in families with multiple cases of systemic lupus erythematosus.

D. Alarcón-Segovia, J. Granados, H. Slor, 1992, Annals of the rheumatic diseases.

Factors associated with fetal losses in severe systemic lupus erythematosus

D. Alarcón-Segovia, J. Alcocer-Varela, C. Arce-Salinas, 1996, Lupus.

Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohort.

Marta E Alarcón-Riquelme, D. Alarcón-Segovia, B. Pons-Estel, 2005, Arthritis and rheumatism.

Erythermalgia: Review of 51 Cases

J. Fairbairn, R. R. Babb, Richard R. Babb, 1964, Circulation.

Association analysis with microsatellite and SNP markers does not support the involvement of BCL-2 in systemic lupus erythematosus in Mexican and Swedish patients and their families

G. Sturfelt, L. Truedsson, D. Alarcón-Segovia, 2000, Genes and Immunity.

Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies.

D. Alarcón-Segovia, A. Cabral, J. Cabiedes, 1995, The Journal of rheumatology.

Antibodies to phospholipid-free beta 2-glycoprotein-I in patients with primary antiphospholipid syndrome.

D. Alarcón-Segovia, A. Cabral, J. Cabiedes, 1995, The Journal of rheumatology.

Vasculitis as a paraneoplastic syndrome. Report of 11 cases and review of the literature.

J. Sánchez-Guerrero, D. Alarcón-Segovia, E. Reyes, 1990, The Journal of rheumatology.

Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices.

J. Sánchez-Guerrero, D. Alarcón-Segovia, M. Cardiel, 1992, The Journal of rheumatology.

Sarcroilaic joints in primary gout. Clinical and roentgenographic study of 143 patients.

E. Díaz-Jouanen, J. Četina, D. Alarcon-segovia, 1973, The American journal of roentgenology, radium therapy, and nuclear medicine.

Isoniazid acetylation rate and development of antinuclear antibodies upon isoniazid treatment.

H. Alcalá, E. Fishbein, D. Alarcon-segovia, 1971, Arthritis and rheumatism.

Systemic lupus erythematosus presenting as panniculitis (lupus profundus).

D. Alarcón-Segovia, R. Messner, E. Díaz-Jouanen, 1975, Annals of internal medicine.

Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus.

D. Alarcón-Segovia, J. Alcocer-Varela, J. Granados, 1997, Arthritis and rheumatism.

CLINICAL AND EXPERIMENTAL STUDIES ON THE HYDRALAZINE SYNDROME AND ITS RELATIONSHIP TO SYSTEMIC LUPUS ERYTHEMATOSUS

K. Wakim, D. Alarcón-Segovia, J. Worthington, 1967, Medicine.

β2-Glycoprotein-I mRNA transcripts are expressed by hepatocytes but not by resting or activated human endothelial cells

D. Alarcón-Segovia, L. Llorente, A. Cabral, 1998 .

Marked destructive changes occurring in osteoarthric finger joints after intra-articular injection of corticosteroids.

D. Alarcón-Segovia, L. Ward, D. Alarcon-segovia, 1966, Arthritis and rheumatism.

Serum immunoglobulins in pulmonary tuberculosis.

D. Alarcón-Segovia, E. Fishbein, D. Alarcon-segovia, 1971, Chest.

HLA-B alleles and complotypes in Mexican patients with seronegative spondyloarthropathies.

D. Alarcón-Segovia, J. Alcocer-Varela, J. Granados, 1994, Annals of the rheumatic diseases.

Probable depiction of juvenile arthritis by Sandro Botticelli.

D. Alarcón-Segovia, J. Alcocer-Varela, A. Laffón, 1983, Arthritis and rheumatism.

Features of Sjögren's syndrome in primary biliary cirrhosis.

D. Alarcón-Segovia, E. Díaz-Jouanen, E. Fishbein, 1973, Annals of internal medicine.

Association between a T cell receptor restriction fragment length polymorphism and systemic lupus erythematosus.

P. Schur, D. Alarcón-Segovia, J. Alcocer-Varela, 1990, The Journal of clinical investigation.

Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus.

D. Alarcón-Segovia, J. Alcocer-Varela, J. Alcocer‐Varela, 1982, The Journal of clinical investigation.

The different faces of shared autoimmunity.

D. Alarcón-Segovia, T. Rodríguez-Reyna, D. Alarcon-segovia, 2006, Autoimmunity reviews.

Human post-thymic precursor cells in health and disease. VI. Effect of serum thymic factor on the response of cells from patients with systemic lupus erythematosus or mixed connective tissue disease in autologous mixed lymphocyte reaction.

D. Alarcón-Segovia, R. Palacios, D. Alarcon-segovia, 1981, Clinical immunology and immunopathology.

PERIPHERAL VASCULAR SYNDROMES ASSOCIATED WITH SYSTEMIC LUPUS ERYTHEMATOSUS.

P. J. Osmundson, D. Alarcón Segovia, D. Alarcon-segovia, 1965, Annals of internal medicine.

SYSTEMIC LUPUS ERYTHEMATOSUS WITH ERYTHERMALGIA.

D. Alarcón-Segovia, J. Fairbairn, R. Babb, 1963, Archives of internal medicine.

Oral manifestations in patients with Sjögren's syndrome.

D. Alarcón-Segovia, A. Villa, A. Soto-Rojas, 1998, The Journal of rheumatology.

Valine/valine genotype at position 247 of the beta2-glycoprotein I gene in Mexican patients with primary antiphospholipid syndrome: association with anti-beta2-glycoprotein I antibodies.

D. Alarcón-Segovia, A. Villa, A. Cabral, 2003, Arthritis and rheumatism.

Autoantibodies in systemic lupus erythematosus.

D. Alarcón-Segovia, A. Cabral, D. Alarcon-segovia, 1996, Current opinion in rheumatology.

Effects of L-canavanine on T cells may explain the induction of systemic lupus erythematosus by alfalfa.

D. Alarcón-Segovia, J. Alcocer-Varela, L. Llorente, 1985, Arthritis and rheumatism.

Differences in the production of and/or the response to interleukin-2 by T lymphocytes from patients with the various connective tissue diseases

D. Alarcón-Segovia, J. Alcocer-Varela, A. Laffón, 2004, Rheumatology International.

Antibody penetration into living cells. II. Anti-ribonucleoprotein IgG penetrates into Tgamma lymphocytes causing their deletion and the abrogation of suppressor function.

D. Alarcón-Segovia, A. Ruiz-Arguelles, L. Llorente, 1979, Journal of immunology.

Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients.

D. Alarcón-Segovia, M. Cardiel, Cardiel Mh, 1989, The Journal of rheumatology.

Hyperprolactinemia inhibits natural killer (NK) cell functionin vivo and its bromocriptine treatment not only corrects it but makes it more efficient

D. Alarcón-Segovia, F. Larrea, A. Villa, 1992, Journal of Clinical Immunology.

Cellular and Humoral Immune Parameters in Women With Pathological Hyperprolactinemia Before and During Treatment With Bromocriptine

D. Alarcón-Segovia, F. Larrea, V. Diaz-sanchez, 1994, American journal of reproductive immunology.

Longitudinal study on the production of and cellular response to interleukin-2 in patients with systemic lupus erythematocus

D. Alarcón-Segovia, J. Alcocer-Varela, J. Alcocer‐Varela, 2004, Rheumatology International.

A major susceptibility locus for systemic lupus erythemathosus maps to chromosome 1q31.

D. Alarcón-Segovia, B. Johanneson, G. Lima, 2002, American journal of human genetics.

One thousand private rheumatology patients in Mexico City.

R. González-Amaro, D. Alarcón-Segovia, F. Ramos-Niembro, 1983, Arthritis and rheumatism.

Mixed connective tissue disease: a disorder of immune regulation.

D. Alarcón-Segovia, D. Alarcon-segovia, 1983, Seminars in arthritis and rheumatism.

Disturbances in the tissue plasminogen activator/plasminogen activator inhibitor (TPA/PAI) system in systemic lupus erythematosus

D. Alarcón-Segovia, G. Ruiz-Argüelles, E. Pacheco-Pantoja, 1991, American journal of hematology.

Anti-neuronal antibodies in antiphospholipid syndrome with central nervous system involvement: the difference from systemic lupus erythematosus

Y. Shoenfeld, D. Mevorach, D. Alarcón-Segovia, 1995, Lupus.

Shared autoimmunity: The time has come

D. Alarcón-Segovia, D. Alarcon-segovia, 2004, Current rheumatology reports.

Immunoregulatory defects in patients with systemic lupus erythematosus in clinical remission

D. Alarcón-Segovia, J. Alcocer-Varela, Y. Richaud-Patin, 2003, Lupus.

3 – ETIOPATHOGENESIS OF SYSTEMIC LUPUS ERYTHEMATOSUS: Itineraries of Three Troikas

D. Alarcón-Segovia, M. Alarcón-Riquelme, D. Alarcon-segovia, 2004 .

Immunoglobulin heavy chain constant-region gene polymorphism in systemic lupus erythematosus.

P. Schur, D. Alarcón-Segovia, J. Granados, 2010, Arthritis and rheumatism.

The role of HLA-DR alleles and complotypes through the ethnic barrier in systemic lupus erythematosus in Mexicans

D. Alarcón-Segovia, J. Alcocer-Varela, J. Granados, 1996, Lupus.

Epitope mapping and reactivity of autoantibodies to the E2 component of 2‐oxoglutarate dehydrogenase complex in primary biliary cirrhosis using recombinant 2‐oxoglutarate dehydrogenase complex

Ross, E. Dickson, D. V. van Thiel, 1996, Hepatology.

Autoimmune thyroid disease in primary Sjögren's syndrome.

D. Alarcón-Segovia, A. Kraus, B. Pérez, 1995, The American journal of medicine.

Broken dogma: penetration of autoantibodies into living cells.

D. Alarcón-Segovia, L. Llorente, A. Ruiz-Argüelles, 1996, Immunology today.

Antibody to nuclear ribonucleoprotein penetrates live human mononuclear cells through Fc receptors

D. Alarcón-Segovia, A. Ruiz-Arguelles, E. Fishbein, 1978, Nature.

Pathogenetic potential of antiphospholipid antibodies.

D. Alarcón-Segovia, D. Alarcon-segovia, 1988, The Journal of rheumatology.

Occurrence of both hemolytic anemia and thrombocytopenic purpura (Evans' syndrome) in systemic lupus erythematosus. Relationship to antiphospholipid antibodies.

D. Alarcón-Segovia, M. Delezé, C. V. Oria, 1988, The Journal of rheumatology.

A bioactive 60-kilodalton prolactin species is preferentially secreted in cultures of mitogen-stimulated and nonstimulated peripheral blood mononuclear cells from subjects with systemic lupus erythematosus.

D. Alarcón-Segovia, J. Alcocer-Varela, F. Larrea, 1997, The Journal of clinical endocrinology and metabolism.

antiphospholipid syndrome Autoantibodies against the fibrinolytic receptor, annexin 2, in

Bihui Huang, J. Sánchez-Guerrero, D. Alarcón-Segovia, 2013 .

Frontiers of SLE: review of the 5th International Congress of Systemic Lupus Erythematosus, Cancun, Mexico, April 20-25, 1998.

Y. Shoenfeld, D. Alarcón-Segovia, T. Koike, 1999, Seminars in arthritis and rheumatism.

Correction of thrombocytopenia with small dose aspirin in the primary antiphospholipid syndrome.

J. Sánchez-Guerrero, D. Alarcón-Segovia, D. Alarcon-segovia, 1989, The Journal of rheumatology.

Immunoregulatory circuits in the acquired immune deficiency syndrome and related complex. Production of and response to interleukins 1 and 2, NK function and its enhancement by interleukin-2 and kinetics of the autologous mixed lymphocyte reaction.

D. Alarcón-Segovia, J. Alcocer-Varela, C. Abud-Mendoza, 1985, Clinical and experimental immunology.

Defective monocyte production of, and T lymphocyte response to, interleukin-1 in the peripheral blood of patients with systemic lupus erythematosus.

D. Alarcón-Segovia, J. Alcocer-Varela, A. Laffón, 1984, Clinical and experimental immunology.

Pha‐Induced Cellular Cytotoxicity

D. Alarcón-Segovia, Alejandro Ruíz‐Arg¨︁elles, Efraín Díz‐Jouanen, 1979 .

Influence of disease duration, continued followup and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with systemic lupus erythematosus.

D. Alarcón-Segovia, A. Villa, C. Drenkard, 1993, The Journal of rheumatology.

Antiphospholipid arterial vasculopathy.

D. Alarcón-Segovia, M. Cardiel, E. Reyes, 1989, The Journal of rheumatology.

Characterization of anti-phosphatidylcholine polyreactive natural autoantibodies from normal human subjects.

D. Alarcón-Segovia, A. Cabral, J. Cabiedes, 2002, Journal of autoimmunity.

The predestination of autoantibodies

Donato Alarcón-Segovia, D. Alarcon-segovia, 2001, Current rheumatology reports.

Hidden anti‐phospholipid antibodies in normal human sera circulate as immune complexes whose antigen can be removed by heat, acid, hypermolar buffers or phospholipase treatments

D. Alarcón-Segovia, A. Cabral, J. Cabiedes, 1998, European journal of immunology.

Phospholipid specificity and requirement of beta 2-glycoprotein-I for reactivity of antibodies from patients with primary antiphospholipid syndrome.

J. Sánchez-Guerrero, D. Alarcón-Segovia, J. Cabiedes, 1992, Journal of autoimmunity.

Bromelain-Treated Erythrocyte Autoantibodies

D. Alarcón-Segovia, A. Cabral, D. Alarcon-segovia, 1996 .

Antibody penetration into living cells. I. Intranuclear immunoglobulin in peripheral blood mononuclear cells in mixed connective tissue disease and systemic lupus erythematosus.

D. Alarcón-Segovia, A. Ruiz-Argüelles, E. Fishbein, 1979, Clinical and experimental immunology.

Splenectomy has a limited role in the management of lupus with thrombocytopenia.

D. Alarcón-Segovia, D. Alarcon-segovia, 2002, The Journal of rheumatology.

Both risk alleles for FcγRIIA and FcγRIIIA are susceptibility factors for SLE: a unifying hypothesis

J. Odeberg, D. Alarcón-Segovia, V. Magnusson, 2004, Genes and Immunity.

Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance.

D. Alarcón-Segovia, S. Rivero, E. Díaz-Jouanen, 1978, Arthritis and rheumatism.

Lymphopenia in systemic lupus erythematosus. Clinical, diagnostic, and prognostic significance.

D. Alarcón-Segovia, S. Rivero, E. Díaz-Jouanen, 1978, Arthritis and rheumatism.

Tween 20 detaches cardiolipin from ELISA plates and makes anticardiolipin antibodies undetectable regardless of the presence of beta 2-glycoprotein-I.

D. Alarcón-Segovia, J. Cabiedes, A. Cabral, 1994, Journal of immunological methods.

Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome

G. Ruiz-Argüelles, A. Ruiz-Argüelles, J. Garcés‐Eisele, 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Both risk alleles for FcgammaRIIA and FcgammaRIIIA are susceptibility factors for SLE: a unifying hypothesis.

J. Odeberg, D. Alarcón-Segovia, V. Magnusson, 2004, Genes and immunity.

Listeriosis in patients with connective tissue diseases.

J. Sifuentes-Osornio, A. Cabral, A. Kraus, 1994, The Journal of rheumatology.

Antiphospholipid Antibodies and the Antiphospholipid Syndrome

D. Alarcón-Segovia, A. Villa, B. Estañol, 1997 .

Systemic Lupus Erythematosus in Males A Study of 107 Latin American Patients

D. Alarcón-Segovia, J. Anaya, M. Cardiel, 1996, Medicine.

Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial.

R. González-Amaro, D. Alarcón-Segovia, A. Kraus, 1984, The Journal of rheumatology.

Oral candidiasis and Sjögren's syndrome.

D. Alarcón-Segovia, A. Villa, A. Soto-Rojas, 1998, The Journal of rheumatology.

T-cell subpopulations in the peripheral blood of patients with connective tissue diseases as determined by flow cytometry using monoclonal antibodies.

D. Alarcón-Segovia, C. Saldate, S. Rivero, 1983, Clinical immunology and immunopathology.

Serum Hyperviscosity in Sjögren's Syndrome: Interaction Between Serum IgG and IgG Rheumatoid Factor

D. Alarcón-Segovia, R. Heimer, E. Fishbein, 1974 .

Will some day PAPS fade into SLE?

D. Alarcón-Segovia, A. Cabral, D. Alarcon-segovia, 1996, Lupus.

Class II allele and haplotype frequencies in Mexican systemic lupus erythematosus patients: the relevance of considering homologous chromosomes in determining susceptibility.

D. Alarcón-Segovia, J. Alcocer-Varela, J. Granados, 2001, Human immunology.

Relationship of anticardiolipin antibodies and antiphospholipid syndrome to HLA-DR7 in Mexican patients with systemic lupus erythematosus (SLE)

D. Alarcón-Segovia, J. Alcocer-Varela, J. Granados, 1997, Lupus.

Immunogenetics of mixed connective tissue disease in a Mexican Mestizo population.

D. Alarcón-Segovia, J. Alcocer-Varela, J. Granados, 1999, Clinical and experimental rheumatology.

Letter to the editor: “Mexican aspirin”—a derogatory term

G. Ruiz-Argüelles, J. Hargis, J. Redmond, 1990 .

SYSTEMIC LUPUS ERYTHEMATOSUS FOLLOWING THYMECTOMY FOR MYASTHENIA GRAVIS: Report of Two Cases

D. Alarcón-Segovia, F. Howard, J. Maldonado, 1963 .

The antiphospholipid/cofactor syndromes. II. A variant in patients with systemic lupus erythematosus with antibodies to beta 2-glycoprotein I but no antibodies detectable in standard antiphospholipid assays.

D. Alarcón-Segovia, A. Cabral, J. Cabiedes, 1997, The Journal of rheumatology.

The necrotizing vasculitides. A new pathogenetic classification.

D. Alarcón-Segovia, D. Alarcon-segovia, 1977, The Medical clinics of North America.

The Concept and Classification of Antiphospholipid/Cofactor Syndromes

D. Alarcón-Segovia, A. Cabral, D. Alarcon-segovia, 1996, Lupus.

Distribution of class I and class III MHC antigens in the Tarasco Amerindians.

D. Alarcón-Segovia, J. Granados, J. Ruiz-Morales, 2002, Human immunology.

Diabetes insipidus secondary to Wegener's granulomatosis: report and review of the literature.

D. Alarcón-Segovia, A. Rosete, A. Cabral, 1991, The Journal of rheumatology.

Connective tissue disorders and the bowel.

D. Alarcón-Segovia, M. A. Cardiel, D. Alarcon-segovia, 1989, Bailliere's clinical rheumatology.

Anticardiolipin and anti-beta2-glycoprotein-I antibodies in hypertensive disorders of pregnancy.

D. Alarcón-Segovia, A. Villa, A. Cabral, 2002, Archives of medical research.

Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo

K. Kalunian, V. Strand, M. Genovese, 2003, Lupus.

Antibody penetration into living cells. IV. Different effects of anti-native DNA and anti-ribonucleoprotein IgG on the cell cycle of activated T gamma cells.

D. Alarcón-Segovia, L. Llorente, D. Alarcon-segovia, 1983, Clinical and experimental immunology.

From benign polyclonal to malignant monoclonal lymphoproliferation in a patient with primary Sjögren's syndrome.

D. Alarcón-Segovia, E. Díaz-Jouanen, G. Ruiz-Argüelles, 1981, Arthritis and rheumatism.

Drug-induced lupus syndromes

D. Alarcón-Segovia, D. Alarcon-segovia, 1969, British medical journal.

Raynaud's phenomenon in primary Sjögren's syndrome. Association with other extraglandular manifestations.

D. Alarcón-Segovia, C. Caballero-Uribe, A. Villa, 1992, The Journal of rheumatology.

How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI).

D. Alarcón-Segovia, M. Cardiel, M. Abello-Banfi, 1993, Clinical and experimental rheumatology.

Splenectomy for hemocytopenia in systemic lupus erythematosus. A controlled appraisal.

D. Alarcón-Segovia, S. Rivero, M. Alger, 1979, Archives of internal medicine.

Immunochemical determination of DNA in immune complexes present in the circulation of patients with systemic lupus erythematosus.

Y. Shoenfeld, D. Alarcón-Segovia, R. Nezlin, 1998, Journal of autoimmunity.

Primary antiphospholipid syndrome as a cause of intestinal infarction.

J. Sánchez-Guerrero, D. Alarcón-Segovia, E. Reyes, 1992, The Journal of rheumatology.

Natural killer cell activity in the systemic connective tissue diseases.

R. González-Amaro, D. Alarcón-Segovia, J. Alcocer-Varela, 1988, The Journal of rheumatology.

Interleukin-1 and Interleukin-6 Activities are Increased in the Cerebrospinal Fluid of Patients with CNS Lupus Erythematosus and Correlate with Local Late T-Cell Activation Markers

D. Alarcón-Segovia, J. Alcocer-Varela, D. Aleman-Hoey, 1992, Lupus.

Activation markers on peripheral blood T cells from patients with active or inactive systemic lupus erythematosus. Correlation with proliferative responses and production of IL-2.

F. Sánchez‐Madrid, D. Alarcón-Segovia, J. Alcocer-Varela, 1991, Journal of autoimmunity.

D. Alarcón-Segovia, A. Kraus, D. Alarcon-segovia, 1991, Bailliere's clinical rheumatology.

Lupus erythematosus cell phenomenon in patients with chronic ulcerative colitis *

D. Alarcón-Segovia, R. G. Shorter, R. Shorter, 1965, Gut.

Neuroendocrine dopaminergic regulation of prolactin release in systemic lupus erythematosus: a possible role of lymphocyte-derived prolactin

D. Alarcón-Segovia, J. Alcocer-Varela, F. Larrea, 2004, Lupus.

Myositis in primary Sjögren's syndrome. Report of 3 cases.

D. Alarcón-Segovia, A. Villa, E. Reyes, 1994, The Journal of rheumatology.

Delay in the onset of systemic lupus erythematosus following treatment with the immunomodulator AS101: association with IL-10 inhibition and increase in TNF-alpha levels.

D. Alarcón-Segovia, U. Gafter, B. Sredni, 1997, Journal of immunology.

Prevalence of battering among 1780 outpatients at an internal medicine institution in Mexico.

D. Alarcón-Segovia, C. Ellertson, C. Díaz-Olavarrieta, 2002, Social science & medicine.

Antibody penetration into living cells: pathogenic, preventive and immuno-therapeutic implications.

D. Alarcón-Segovia, A. Ruiz-Argüelles, L. Rivadeneyra-Espínoza, 2003, Current pharmaceutical design.

Massive pulmonary hemorrhage in mixed connective tissue diseases.

J. Sánchez-Guerrero, G. Cesarman, D. Alarcon-segovia, 1989, The Journal of rheumatology.

The recovery of self tolerance in SLE

D. Alarcón-Segovia, D. Alarcon-segovia, 2001, Lupus.

Update: Treatment of systemic lupus erythematosus

D. Alarcón-Segovia, D. Alarcon-segovia, 2002 .

Antibodies to histones in systemic lupus erythematosus.

D. Alarcón-Segovia, J. Vega, E. Fishbein, 1979, Clinical and experimental immunology.

Decreased circulating thymus-derived cells with receptors for the Fc portion of immunoglobulin G in systemic lupus erythematosus.

D. Alarcón-Segovia, A. Ruiz-Argüelles, D. Alarcon-segovia, 1978, The Journal of clinical investigation.

The future of treatment for systemic lupus erythematosus.

D. Alarcón-Segovia, D. Alarcon-segovia, 2001, The Israel Medical Association journal : IMAJ.

Bilateral renal vein thrombosis and nephrotic syndrome in a patient with the Marfan syndrome.

D. Alarcón-Segovia, F. Díes, F. Fierro, 1968, Diseases of the chest.

Carbamazepine for tabetic pain.

D. Alarcon-segovia, M. Lazcano, 1968, JAMA.

Systemic lupus erythematosus as a cause and prognostic factor of acute pancreatitis.

D. Alarcón-Segovia, J. Alcocer-Varela, A. Duarte-Rojo, 2004, The Journal of rheumatology.

Mixed connective tissue disease and overlap syndromes.

D. Alarcón-Segovia, D. Alarcon-segovia, 1994, Clinics in dermatology.

Australia antigen in systemic lupus.

D. Alarcón-Segovia, E. Fishbein, D. Alarcon-segovia, 1971, The New England journal of medicine.

Box 1. Autoantibodies that penetrate cells

D. Alarcón-Segovia, L. Llorente, Alejandro Ruiz-Argielles, 1996 .

Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus

J. Alcocer-Varela, J. Wijdenes, Y. Richaud-Patin, 1995, The Journal of experimental medicine.

Spontaneous production of, and defective response to, interleukin-1 by peripheral blood mononuclear cells from patients with scleroderma.

D. Alarcón-Segovia, J. Alcocer-Varela, E. Martínez‐Cordero, 1985, Clinical and experimental immunology.

T-cell dysregulation in patients with hyperprolactinemia: effect of bromocriptine treatment.

D. Alarcón-Segovia, J. Alcocer-Varela, F. Larrea, 1986, Clinical immunology and immunopathology.

Autoantibodies that Penetrate into Living Cells

D. Alarcón-Segovia, L. Llorente, A. Ruiz-Argüelles, 1996 .

Human Post‐thymic Precursor Cells in Health and Disease

D. Alarcón-Segovia, R. Palacios, D. Alarcon-segovia, 1981, Scandinavian journal of immunology.

Genetic analysis of the contribution of IL10 to systemic lupus erythematosus.

U. Gyllensten, L. Klareskog, L. Truedsson, 1999, The Journal of rheumatology.

Stimulatory effect of metoclopramide on the esophagus and lower esophageal sphincter of patients with pss

D. Alarcón-Segovia, G. Ibáñez, M. Ramirez-mata, 1977 .

The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients With Systemic Lupus Erythematosus: Ethnic and Disease Heterogeneity Among “Hispanics”

E. Soriano, B. Pons-Estel, A. Villa, 2004, Medicine.

Malabsorption in rheumatoid arthritis: an unusual complication caused by amyloidosis.

D. Alarcón-Segovia, J. Mcpherson, R. Babb, 1967, Arthritis and rheumatism.

Penetrating anti-DNA monoclonal antibodies induce activation of human peripheral blood mononuclear cells.

T. Ternynck, R. González-Amaro, D. Alarcón-Segovia, 1998, Journal of autoimmunity.

Antibody penetration into living cells. V. Interference between two fc gamma receptor-mediated functions: antibody penetration and antibody-dependent cellular cytotoxicity.

E. Díaz-Jouanen, L. Llorente, A. Ruiz-Argüelles, 1981, Immunology.

International Symposium Art, History and Antiquity of Rheumatic Diseases

P. Dieppe, T. Appelboom, E. Bywaters, 1986, Clinical Rheumatology.

URACIL-SPECIFIC ANTI-R.N.A. ANTIBODIES IN SCLERODERMA

D. Alarcón-Segovia, S. Estrada-Parra, E. Fishbein, 1975, The Lancet.

ANTIBODY PENETRATION INTO LIVING CELLS: MECHANISMS AND CONSEQUENCES

D. Alarcón-Segovia, A. Ruiz-Argüelles, D. Alarcon-segovia, 1980 .

A method for high yield isolation and purification of anti-native DNA antibodies present in lupus sera.

D. Alarcón-Segovia, E. Fishbein, D. Alarcon-segovia, 1980, Journal of immunological methods.

Lupus subsets: relationship to genetic and environmental factors.

D. Alarcón-Segovia, E. Díaz-Jouanen, D. Alarcon-segovia, 1980, Seminars in arthritis and rheumatism.

Drug-Induced Antinuclear Antibodies and Lupus Syndromes

D. Alarcón-Segovia, D. Alarcon-segovia, 2012, Drugs.

Cold-reactive lymphocytotoxic antibodies in mixed connective tissue disease.

D. Alarcón-Segovia, E. Díaz-Jouanen, L. Llorente, 1977, The Journal of rheumatology.

Sjögren's syndrome in systemic lupus erythematosus. Clinical and subclinical manifestations.

D. Alarcón-Segovia, G. Ibáñez, J. Hérnandez-Ortiz, 1974 .

Sjögren's syndrome in progressive systemic sclerosis (scleroderma).

D. Alarcón-Segovia, G. Ibáñez, J. Hérnandez-Ortiz, 1974, The American journal of medicine.

Interferon production by lymphocytes from patients with systemic lupus erythematosus.

E. Fishbein, J. Ruiz-Gómez, D. Alarcon-segovia, 1974, Arthritis and rheumatism.

Are there “Attenuated” Forms of Evans Syndrome?

D. Alarcón-Segovia, G. Ruiz-Argüelles, B. López-Martínez, 2001, Hematology.

Transient seropositive arthritis after thermal injury.

P. Reyes, D. Alarcon-segovia, 1972, Lancet.

LUPUS DIATHESIS AND THE HYDRALAZINE SYNDROME.

K. Wakim, J. Worthington, L. Ward, 1965, The New England journal of medicine.

Antinuclear antibodies and propylthiouracil therapy.

D. Alarcón-Segovia, E. Fishbein, J. Četina, 1972, JAMA.

Isoniazid, antinuclear antibodies and SLE.

D. Alarcón-Segovia, D. Alarcon-segovia, 1973, Chest.

Mixed connective tissue disease: Some statements

D. Alarcón-Segovia, D. Alarcon-segovia, 1982, Clinical Rheumatology.

CHAPTER 5 – Scleroderma

D. Alarcón-Segovia, D. Alarcon-segovia, 1985 .

Antibody penetration into living cells. III. Effect of antiribonucleoprotein IgG on the cell cycle of human peripheral blood mononuclear cells.

D. Alarcón-Segovia, A. Ruiz-Arguelles, L. Llorente, 1982, Clinical immunology and immunopathology.

Antibodies to nucleoprotein and to hydrazide-altered soluble nucleoprotein in tuberculous patients receiving isoniazid.

E. Fishbein, V. Betancourt, D. Alarcon-segovia, 1969, Clinical and Experimental Immunology.

Immunochemical characterization of the anti-RNA antibodies found in scleroderma and systemic lupus erythematosus. I. Differences in reactivity with Poly (U) and Poly-(A) Poly (U).

D. Alarcón-Segovia, E. Fishbein, D. Alarcon-segovia, 1975, Journal of immunology.

Effect of pregnancy on functions of circulating T cells from patients with systemic lupus erythematosus: correction of T-cell suppression and autologous mixed-lymphocyte responses.

D. Alarcón-Segovia, J. Alcocer-Varela, E. Díaz-Jouanen, 1983, Clinical immunology and immunopathology.

Abnormalities in the content of nucleic acids of peripheral blood mononuclear cells from patients with systemic lupus erythematosus.

D. Alarcón-Segovia, E. Díaz-Jouanen, L. Llorente, 1982, Arthritis and rheumatism.

Human postthymic precursor cells in health and disease. VII. Immunoregulatory circuits of the peripheral blood mononuclear cells from patients with progressive systemic sclerosis.

D. Alarcón-Segovia, R. Palacios, G. Ibáñez de Kasep, 1981, Journal of clinical & laboratory immunology.

Cimetidine abrogates suppressor T cell function in vitro.

R. Palacios, D. Alarcon-segovia, 1981, Immunology letters.

Heterogeneity of the spontaneously expanded and mitogen-induced generation of suppressor cell function of T cells on B cells in systemic lupus erythematosus.

D. Alarcón-Segovia, A. Ruiz-Arguelles, L. Llorente, 1980, Arthritis and rheumatism.

Suppressor cell loss and dysfunction in mixed connective tissue disease.

D. Alarcón-Segovia, A. Ruiz-Arguelles, D. Alarcon-segovia, 1980, Arthritis and rheumatism.

Echocardiographic evaluation of patients with rheumatoid arthritis

D. Alarcón-Segovia, A. Iglesias-Gamarra, M. Peña, 1983, Clinical Rheumatology.

The range and specificity of antinuclear antibodies in systemic lupus erythematosus.

D. Alarcón-Segovia, H. Alcalá, S. Estrada-Parra, 1970, Clinical and experimental immunology.

Antinuclear antibodies in patients on anticonvulsant therapy.

D. Alarcón-Segovia, P. Reyes, E. Fishbein, 1972, Clinical and experimental immunology.

Lupus erythematosus cell phenomenon in patients with chronic ulcerative colitis *

R. G. Shorter, T. Herskovic, L. G. Bartholomew, 1965, Gut.

Antigenic specificity of chlorpromazine-induced antinuclear antibodies.

D. Alarcón-Segovia, E. Fishbein, R. Raya, 1973, Clinical and experimental immunology.

Presence of hepatitis-associated antigen in systemic lupus erythematosus.

D. Alarcón-Segovia, E. Díaz-Jouanen, E. Fishbein, 1972, Clinical and experimental immunology.

Differences in immunoregulatory T cell circuits between diphenylhydantoin-related and spontaneously occurring systemic lupus erythematosus.

D. Alarcón-Segovia, R. Palacios, D. Alarcon-segovia, 1981, Arthritis and rheumatism.

Course and Prognosis of the Antiphospholipid Syndrome

D. Alarcón-Segovia, C. Drenkard, D. Alarcon-segovia, 2002 .

Immunoglobulin light-chain type in Sjögren's syndrome.

E. Díaz-Jouanen, G. Ruiz-Argüelles, D. Alarcon-segovia, 1983, Human pathology.

Does the thymus play opposite roles in SLE and myasthenia gravis?

D. Alarcón-Segovia, J. R. de la Fuente, S. Rivero, 1978, Arthritis and rheumatism.

Natural killer cell activity in dermatomyositis-polymyositis.

R. González-Amaro, D. Alarcón-Segovia, J. Alcocer-Varela, 1987, The Journal of rheumatology.

Fine mapping of the SLEB2 locus involved in susceptibility to systemic lupus erythematosus.

J. Terwilliger, R. Jonsson, A. Bolstad, 2000, Genomics.

INFARCTION AND CIRCULATING ANTICOAGULANT

D. Alarcon-segovia, 1967 .

Comparative Effectiveness of Packages of Treatment Including Ultrasound or Transcutaneous Electrical Nerve Stimulation in Painful Shoulder Syndrome

D. Alarcón-Segovia, M. Cardiel, Isabel Herrera-Lasso, 1993 .

Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus.

D. Alarcón-Segovia, A. Villa, C. Drenkard, 1994, The Journal of rheumatology.

Mononuclear cell-fibroblast interactions in scleroderma.

R. González-Amaro, D. Alarcón-Segovia, J. Alcocer-Varela, 1988, Clinical immunology and immunopathology.

T lymphocyte subsets, suppressor and contrasuppressor cell functions, and production of interleukin-2 in the peripheral blood of rheumatic fever patients and their apparently healthy siblings.

D. Alarcón-Segovia, J. Alcocer-Varela, M. Alarcón‐Riquelme, 1990, Clinical immunology and immunopathology.

Some patients with primary antiphospholipid syndrome have increased circulating CD5+ B cells that correlate with levels of IgM antiphospholipid antibodies.

J. Sánchez-Guerrero, D. Alarcón-Segovia, J. Alcocer-Varela, 1991, Clinical and experimental rheumatology.

LYMPHOCYTOTOXIC ANTIBODIES DURING PREGNANCY IN SYSTEMIC LUPUS ERYTHEMATOSUS

E. Díaz-Jouanen, H. Lom-Orta, D. Alarcon-segovia, 1979, The Lancet.

Protein S deficiency associated to anti-protein S antibodies in a patient with mixed connective-tissue disease and its reversal by danazol.

D. Alarcón-Segovia, G. Ruiz-Argüelles, A. Ruiz-Argüelles, 1993, Acta haematologica.

Overlap syndromes in the context of shared autoimmunity

D. Alarcón-Segovia, T. Rodríguez-Reyna, D. Alarcon-segovia, 2005, Autoimmunity.

Lymphocytotoxic antibodies in mexican patients with systemic lupus erythematosus and their families relationship of disease activity in the probands to antibody cytotoxicity in their relatives.

R. Messner, R. DeHoratius, E. Fishbein, 1981, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

The Mosaic of Systemic Lupus Erythematosus: Highlights of the Third International Conference on SLE 13-15 April 1992

Y. Shoenfeld, D. Alarcon-segovia, 1992, Lupus.

Serum anti-β2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients

D. Alarcón-Segovia, A. Cabral, C. Drenkard, 1999 .

Serum anti-beta2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients.

D. Alarcón-Segovia, A. Villa, A. Cabral, 1999, The American journal of medicine.

Functional and immunochemical heterogeneity of antiphospholipid antibodies: a classification.

D. Alarcón-Segovia, A. Cabral, D. Alarcon-segovia, 1992, The Journal of rheumatology.

Hemolytic anemia related to an IgM autoantibody to phosphatidylcholine that binds in vitro to stored and to bromelain-treated human erythrocytes.

D. Alarcón-Segovia, A. Cabral, J. Cabiedes, 1990, Journal of autoimmunity.

Fever in adult onset Still's disease. Response to methotrexate.

D. Alarcón-Segovia, A. Kraus, D. Alarcon-segovia, 1991, The Journal of rheumatology.

Behçet's disease. Report of twelve patients in the Mexican population.

D. Alarcón-Segovia, R. Enríquez, J. A. del Giudice-Knipping, 1981, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

Retinal microangiopathy in systemic lupus erythematosus.

D. Alarcón-Segovia, R. Santos, E. Barojas, 1975, American journal of ophthalmology.

A comparison of genome-scans performed in multicase families with systemic lupus erythematosus from different population groups.

G. Sturfelt, U. Gyllensten, L. Klareskog, 1999, Journal of autoimmunity.

The mechanism of action of L-canavanine in inducing autoimmune phenomena.

D. Alarcón-Segovia, J. Alcocer-Varela, J. Alcocer‐Varela, 1985 .

Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus.

J. Sánchez-Guerrero, D. Alarcón-Segovia, C. Drenkard, 1989, The Journal of rheumatology.

Serum antibodies to distinct epitopes of the tissue‐type plasminogen activator (t‐PA) in patients with systemic lupus erythematosus

D. Alarcón-Segovia, A. Ruiz-Arguelles, P. Gaussem, 1995, American journal of hematology.

[Sjögren's syndrome associated with thymoma].

D. Alarcon-segovia, J. L. Zavala-Mejía, 1971, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

Chronic interstitial cystitis as an initial major manifestation of systemic lupus erythematosus.

D. Alarcón-Segovia, A. R. de la Serna, D. Alarcon-segovia, 1981, The Journal of rheumatology.

Antiphospholipid Syndrome Within Systemic Lupus Erythematosus

D. Alarcón-Segovia, Donato Alarcon-Segovia, D. Alarcon-segovia, 1994, Lupus.

Stimulating and differentiation factors for human B lymphocytes in systemic lupus erythematosus.

D. Alarcón-Segovia, J. Alcocer-Varela, E. Martínez‐Cordero, 1986, Clinical and experimental immunology.

Mixed Connective Tissue Disease in Childhood: Relationship With Sjögren's Syndrome

A. Fraga, F. Ramos-Niembro, J. Gudiño, 1978 .

The contribution of resting heart rate and routine blood tests to the clinical assessment of disease activity in systemic lupus erythematosus.

D. Alarcón-Segovia, M. Cardiel, J. Guzman, 1994, The Journal of rheumatology.

HLA-DR6 (possibly DRB1*1301) is associated with susceptibility to Takayasu arteritis in Mexicans

D. Alarcón-Segovia, J. Yamamoto-Furusho, J. Granados, 2005, Heart and Vessels.

Remission of Systemic Lupus Erythematosus

D. Alarcón-Segovia, C. García-Padilla, C. Drenkard, 1996 .

Anti-Cardiolipin, Anti-Cardiolipin Plus Bovine, or Human β2Glycoprotein-I and Anti-Human β2Glycoprotein-I Antibodies in a Healthy Infant Population

D. Alarcón-Segovia, A. Cabral, J. Cabiedes, 2002 .

Anti-cardiolipin, anti-cardiolipin plus bovine, or human beta(2)glycoprotein-I and anti-human beta(2)glycoprotein-I antibodies in a healthy infant population.

A. Cabral, J. Cabiedes, A. Loredo-Abdalá, 2002, Archives of medical research.

Association of HLA-DR5 (possibly DRB1*1201) with the primary antiphospholipid syndrome in Mexican patients.

D. Alarcón-Segovia, J. Alcocer-Varela, J. Granados, 1995, Arthritis and rheumatism.

Acquired protein C deficiency in a patient with primary antiphospholipid syndrome. Relationship to reactivity of anticardiolipin antibody with thrombomodulin.

D. Alarcón-Segovia, A. Ruiz-Arguelles, G. Ruiz-Argüelles, 1989, The Journal of rheumatology.